BioWorld MedTech

Oct. 28, 2010

Low-cost ultrasound disrupts high-priced chemotherapy

PARIS – A four-minute ultrasound exam can determine in the first 30 days of treatment whether troublesome and often brutally expensive chemotherapy should be stopped, continued or even enhanced. (Medical Device Daily) Read More

Device companies anticipate growth, despite challenges

Elekta's Symmetry now gives 4-D view of moving tumors

Washington roundup: FDA warning takes aim at another PACS systems firm

Deals roundup: BSX completes Asthmatx acquisition for $193.5M

MDD's food for med-tech thought

Financings roundup: Pacific Biosciences to raise $200M in IPO at $16 a share

HIT roundup: NY aims for country's largest EMR network

Agreements/contracts: Myriad, Abbott to assess BRCA mutation testing

Product Briefs

MDD's Ortho Extra

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...